404
Buprenorphine Hydrochloride Market Report
Buprenorphine Hydrochloride Market, Dynamics, Trends, and Market Insights
The report on the Buprenorphine Hydrochloride Market is segmented by Type (Tablets and Injection), By Application (Analgesic and Opioid Antagonist) and Region. It also covers the COVID-19 Impact Analysis and Forecast to 2026. This market research report provides in-depth information on trends, dynamics, revenue opportunities, competitive landscape, and recent developments in the global Buprenorphine Hydrochloride market. The historic years considered for the study are 2016-2019, the base year is 2020, the estimated year is 2021, and the forecast period is 2022-2026.
Buprenorphine hydrochloride is a type of medicine used to treat dependence or addiction to opioids. Buprenorphine comes from the class of drugs called mixed opioid agonist-antagonists.
Siegfried (Switzerland), Resonance-labs (India), Mallinckrodt (UK), Sanofi (France), Arevipharma (Germany), Johnson Matthey (UK), Rusan Pharma (India), Unichemlabs (India), Noramco (The U.S), Sun Pharma (India) and Micro Orgo Chem (India) are among the key players in the buprenorphine hydrochloride market.
North America is expected to grow at high CAGR in the buprenorphine hydrochloride market in the coming years.
Tablets form of buprenorphine hydrochlorides has been recorded for the highest share in the buprenorphine hydrochloride market.
Increasing opioid addiction cases is the major factor driving the growth of buprenorphine hydrochloride market.
Manufacturing Organizations, Distributors & Suppliers, Government as well as Independent Regulatory Authorities, Research Institute / Education Institute, Potential Investors are the target audience in the buprenorphine hydrochloride market.